The Zhitong Finance App learned that Citibank released a research report saying that the bank held an expert meeting with key SANOVO researchers on November 5 to further strengthen the positive view on the potential of savolitinib for EGFR mutant non-small cell lung cancer after first-line and osimertinib treatment, maintain a “buy/high risk” rating, and listed Hewong Pharmaceutical (00013.HK) as the new preferred stock. The target price was raised from HK$40.1 to HK$43.2.

The Zhitong Finance App learned that Citibank released a research report saying that the bank held an expert meeting with key SANOVO researchers on November 5 to further strengthen the positive view on the potential of savolitinib for EGFR mutant non-small cell lung cancer after first-line and osimertinib treatment, maintain a “buy/high risk” rating, and listed Hewong Pharmaceutical (00013.HK) as the new preferred stock. The target price was raised from HK$40.1 to HK$43.2.